Abstract:

Alzheimer’s disease (AD) is the most common cause of dementia globally and represents a profound public health and societal challenge. Until recently, treatment options in Europe were limited to symptomatic therapies offering modest benefit without influencing underlying disease progression. However, 2025 marks a pivotal moment in European Alzheimer’s care, with the approval of the first disease-modifying therapy and a rapidly expanding pipeline of experimental agents that target amyloid, tau, inflammation, synaptic loss, and other pathogenic pathways. This article provides an overview of the latest therapeutic advances in Alzheimer’s disease across Europe, summarising regulatory milestones, key mechanisms of emerging drugs, and major clinical trials currently underway. It also discusses the challenges that health systems face in adopting these therapies, including diagnostic infrastructure, biomarker access, cost, safety monitoring, and equitable distribution. Despite these barriers, the outlook for Alzheimer’s research in Europe is increasingly optimistic, with advances in precision medicine, biomarker development, and collaborative research networks poised to reshape the clinical landscape. Ensuring that these innovations translate into real-world benefit will require coordinated investment, policy leadership, and long-term commitment to dementia care across the continent.

Keywords:

ALZHEIMER’S DISEASE; DEMENTIA; EUROPE; DISEASE-MODIFYING THERAPY; AMYLOID ANTIBODIES; <br /> TAU THERAPIES; CLINICAL TRIALS; NEURODEGENERATION; BIOMARKER DIAGNOSTICS.